Christopher J M Williams, Jenny F Seligmann, Faye Elliott, Michael Shires, Susan D Richman, Sarah Brown, Liping Zhang, Shalini Singh, Judith Pugh, Xiao-Meng Xu, Andrea Muranyi, Christoph Guetter, Auranuch Lorsakul, Uday Kurkure, Zuo Zhao, Jim Martin, Xingwei Wang, Kien Nguyen, Wen-Wei Liu, Dongyao Yan, Nicholas P West, Jennifer H Barrett, Michael Barnes, Isaac Bai, Matthew T Seymour, Philip Quirke, Kandavel Shanmugam
PURPOSE: High tumor mRNA levels of the EGFR ligands amphiregulin (AREG) and epiregulin (EREG) are associated with anti-EGFR agent response in metastatic colorectal cancer (mCRC). However, ligand RNA assays have not been adopted into routine practice due to issues with analytic precision and practicality. We investigated whether AREG/EREG IHC could predict benefit from the anti-EGFR agent panitumumab. EXPERIMENTAL DESIGN: Artificial intelligence algorithms were developed to assess AREG/EREG IHC in 274 patients from the PICCOLO trial of irinotecan with or without panitumumab (Ir vs...
June 15, 2021: Clinical Cancer Research